Skip to main content
. 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112

FIGURE 2.

FIGURE 2

Donanemab (LY3002813) mean plasma concentration‐time profile after the administration of a single dose of donanemab in patients with mild cognitive impairment due to Alzheimer's disease or mild to moderate Alzheimer's disease dementia. HV, heathy volunteers; IV, intravenous; SC, subcutaneous